Publications 2024

Lauritzen T, Munkhaugen J, Bergan S, Peersen K, Svarstad AC, Andersen AM, Pahnke J, Husebye E, Vethe NT (2024)
The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study
Atheroscler Plus, 55, 31-38
DOI 10.1016/j.athplu.2024.01.001, PubMed 38293288

Pivoriunas J, Vethe NT, Husebye E, Fagerland MW, Bergan S, Kristiansen O, Prof JM, Sverre E (2024)
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Eur Heart J Cardiovasc Pharmacother (in press)
DOI 10.1093/ehjcvp/pvae001, PubMed 38196131

Publications 2023

Lauritzen T, Munkhaugen J, Peersen K, Kristiansen O, Sverre E, Nebauer SD, Villseth M, Andersen AM, Svarstad AC, Jensen EP, Bergan S, Husebye E, Vethe NT (2023)
Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms
Clin Pharmacol Ther, 113 (4), 887-895
DOI 10.1002/cpt.2844, PubMed 36622792

Sverre E, Munkhaugen J, Kristiansen O, Weedon-Fekjaer H, Peersen K, Gjertsen E, Gullestad L, Bergan S, Husebye E, Vethe NT (2023)
Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease
Pharmacol Res Perspect, 11 (3), e01089
DOI 10.1002/prp2.1089, PubMed 37186070

Tuv SS, Spigset O, Jensen E, Vethe NT, Nordal K (2023)
[Not Available]
Tidsskr Nor Laegeforen, 143 (13)
DOI 10.4045/tidsskr.23.0496, PubMed 37753760

Vethe NT, Åsberg A, Andersen AM, Heier Skauby R, Bergan S, Midtvedt K (2023)
Clinical performance of volumetric finger-prick sampling for the monitoring of tacrolimus, creatinine and haemoglobin in kidney transplant recipients
Br J Clin Pharmacol, 89 (12), 3690-3701
DOI 10.1111/bcp.15870, PubMed 37537150

Publications 2022

Sverre E, Peersen K, Kristiansen O, Fagerland MW, Perk J, Husebye E, Vethe NT, Dammen T, Munkhaugen J (2022)
Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self-perceived muscle side effects
J Intern Med, 291 (6), 891-893
DOI 10.1111/joim.13454, PubMed 35103360

Vethe NT, Husebye E, Andersen AM, Bergan S, Kristiansen O, Fagerland MW, Munkhaugen J (2022)
Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma
Ther Drug Monit, 44 (4), 558-567
DOI 10.1097/FTD.0000000000000992, PubMed 35482468

Publications 2021

Andersen AM, Bergan S, Gedde-Dahl T, Buechner J, Vethe NT (2021)
Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients
J Pharm Biomed Anal, 203, 114216
DOI 10.1016/j.jpba.2021.114216, PubMed 34182411

Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S et al. (2021)
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Ther Drug Monit, 43 (2), 150-200
DOI 10.1097/FTD.0000000000000871, PubMed 33711005

Brede C, Vethe NT, Skadberg Ø (2021)
The Question of Accuracy Versus Interlaboratory Agreement for Monitoring the Immunosuppressants Everolimus and Sirolimus
Ther Drug Monit, 43 (3), 444-446
DOI 10.1097/FTD.0000000000000892, PubMed 33840796

Kindem IA, Bjerre A, Åsberg A, Midtvedt K, Bergan S, Vethe NT (2021)
Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study
Ther Drug Monit, 43 (3), 371-375
DOI 10.1097/FTD.0000000000000873, PubMed 33596033

Kristiansen O, Sverre E, Peersen K, Fagerland MW, Gjertsen E, Gullestad L, Perk J, Dammen T, Husebye E, Vethe NT, Munkhaugen J (2021)
The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease
Atherosclerosis, 336, 23-29
DOI 10.1016/j.atherosclerosis.2021.09.020, PubMed 34610521

Kristiansen O, Vethe NT, Peersen K, Wang Fagerland M, Sverre E, Prunés Jensen E, Lindberg M, Gjertsen E, Gullestad L, Perk J, Dammen T, Bergan S, Husebye E, Otterstad JE, Munkhaugen J (2021)
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
Eur Heart J Cardiovasc Pharmacother, 7 (6), 507-516
DOI 10.1093/ehjcvp/pvaa076, PubMed 32609361

Peersen K, Munkhaugen J, Sverre E, Kristiansen O, Fagerland M, Vethe NT, Perk J, Husebye E, Dammen T (2021)
Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects
BMC Cardiovasc Disord, 21 (1), 596
DOI 10.1186/s12872-021-02422-7, PubMed 34915854

Skauby RH, Bergan S, Andersen AM, Vethe NT, Christensen H (2021)
In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance
Basic Clin Pharmacol Toxicol, 129 (6), 427-436
DOI 10.1111/bcpt.13645, PubMed 34396687

Skauby RH, Gustavsen MT, Andersen AM, Bjerre A, Åsberg A, Midtvedt K, Vethe NT, Bergan S (2021)
Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients
Ther Drug Monit, 43 (2), 247-255
DOI 10.1097/FTD.0000000000000835, PubMed 33181621

Publications 2020

Amrutkar M, Vethe NT, Verbeke CS, Aasrum M, Finstadsveen AV, Sántha P, Gladhaug IP (2020)
Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123628, PubMed 33287390

Gustavsen MT, Midtvedt K, Robertsen I, Woillard JB, Debord J, Klaasen RA, Vethe NT, Bergan S, Åsberg A (2020)
Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
Clin Transl Sci, 13 (6), 1327-1335
DOI 10.1111/cts.12833, PubMed 32652886

Gustavsen MT, Midtvedt K, Vethe NT, Robertsen I, Bergan S, Åsberg A (2020)
Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling
Ther Drug Monit, 42 (3), 407-414
DOI 10.1097/FTD.0000000000000697, PubMed 31479042

Klaasen RA, Bergan S, Bremer S, Hole K, Nordahl CB, Andersen AM, Midtvedt K, Skauby MH, Vethe NT (2020)
Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation
Br J Clin Pharmacol, 86 (6), 1100-1112
DOI 10.1111/bcp.14218, PubMed 31925806

Kvamsøe MM, Hansen KR, Skadberg Ø, Vethe NT, Brede C (2020)
Salting Out-Assisted Liquid-Liquid Extraction for Liquid Chromatography-Tandem Mass Spectrometry Measurement of Tacrolimus, Sirolimus, Everolimus, and Cyclosporine a in Whole Blood
Ther Drug Monit, 42 (5), 695-701
DOI 10.1097/FTD.0000000000000794, PubMed 32701594

Lemaitre F, Vethe NT, D'Avolio A, Tron C, Robertsen I, De Winter B, Denicolo A, Koch BCP, Venkataramanan R, Van Gelder T, Brunet M, Bergan S, Hesselink DA, Wallemacq P (2020)
Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel
Ther Drug Monit, 42 (5), 665-670
DOI 10.1097/FTD.0000000000000780, PubMed 32520841

Publications 2019

Bergström M, Müller M, Karlsson M, Scholz H, Vethe NT, Korsgren O (2019)
Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells
Cell Transplant, 28 (12), 1603-1613
DOI 10.1177/0963689719872488, PubMed 31512504

Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O et al. (2019)
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Ther Drug Monit, 41 (3), 261-307
DOI 10.1097/FTD.0000000000000640, PubMed 31045868

Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, Fellström B, Holdaas H, Åsberg A, Bergan S, Vethe NT, Warren DJ (2019)
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther Drug Monit, 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580, PubMed 30633722

Kristiansen O, Vethe NT, Fagerland MW, Bergan S, Munkhaugen J, Husebye E (2019)
A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
Br J Clin Pharmacol, 85 (12), 2878-2885
DOI 10.1111/bcp.14122, PubMed 31495943

Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E (2019)
Statin-associated muscle symptoms in coronary patients: design of a randomized study
Scand Cardiovasc J, 53 (3), 162-168
DOI 10.1080/14017431.2019.1612085, PubMed 31030568

Tuv SS, Nordal K, Vethe NT, Bergan S (2019)
Pharmacogenetics in personalised drug therapy
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.19.0055, PubMed 31062549

Tuv SS, Vethe NT, Bergan S, Nordal K (2019)
Pharmacogenetics in personalised drug therapy
Tidsskr. Nor. Laegeforen., 139 (8), 700-702

Vethe NT, Gustavsen MT, Midtvedt K, Lauritsen ME, Andersen AM, Åsberg A, Bergan S (2019)
Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients
Ther Drug Monit, 41 (5), 607-614
DOI 10.1097/FTD.0000000000000655, PubMed 31584926

Vethe NT, Munkhaugen J, Andersen AM, Husebye E, Bergan S (2019)
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry
Ther Drug Monit, 41 (1), 19-28
DOI 10.1097/FTD.0000000000000578, PubMed 30633723

Publications 2018

Klaasen RA, Bergan S, Bremer S, Daleq L, Andersen AM, Midtvedt K, Skauby MH, Vethe NT (2018)
Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
Ther Drug Monit, 40 (5), 558-566
DOI 10.1097/FTD.0000000000000539, PubMed 30086087

Krogstad V, Vethe NT, Robertsen I, Hasvold G, Ose AD, Hermann M, Andersen AM, Chan J, Skauby M, Svensson MHS, Åsberg A, Christensen H (2018)
Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies
Ther Drug Monit, 40 (3), 292-300
DOI 10.1097/FTD.0000000000000510, PubMed 29578937

Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernæs KH, Vethe NT, Prescott E, Jensen SE, Rødevand O, Jortveit J, Bendz B, Schirmer H, Køber L, Bøtker HE, Larsen AI, Vikenes K, Steigen T, Wiseth R, Pedersen T, Edvardsen T, Otterstad JE, Atar D (2018)
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study
Am Heart J, 208, 37-46
DOI 10.1016/j.ahj.2018.10.005, PubMed 30530121

Publications 2017

Bremer S, Vethe NT, Skauby M, Kasbo M, Johansson ED, Midtvedt K, Bergan S (2017)
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation
Br J Clin Pharmacol, 83 (11), 2494-2502
DOI 10.1111/bcp.13367, PubMed 28686294

Skauby RH, Bjerre A, Sæves I, Vethe NT, Bremer S, Svarstad A, Bergan S (2017)
Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study
Ther Drug Monit, 39 (5), 472-482
DOI 10.1097/FTD.0000000000000439, PubMed 28749817

Publications 2016

Kloster-Jensen K, Sahraoui A, Vethe NT, Korsgren O, Bergan S, Foss A, Scholz H (2016)
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J Diabetes Res, 2016, 4196460
DOI 10.1155/2016/4196460, PubMed 26885529

Publications 2015

Bergan S, Bremer S, Vethe NT (2015)
Drug target molecules to guide immunosuppression
Clin Biochem, 49 (4-5), 411-8
DOI 10.1016/j.clinbiochem.2015.10.001, PubMed 26453533

Kloster-Jensen K, Vethe NT, Bremer S, Abadpour S, Korsgren O, Foss A, Bergan S, Scholz H (2015)
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro
Transpl Int, 28 (10), 1152-61
DOI 10.1111/tri.12617, PubMed 26046470

Robertsen I, Vethe NT, Midtvedt K, Falck P, Christensen H, Åsberg A (2015)
Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations
Ther Drug Monit, 37 (5), 675-80
DOI 10.1097/FTD.0000000000000185, PubMed 25565673

Robertsen I, Åsberg A, Ingerø AO, Vethe NT, Bremer S, Bergan S, Midtvedt K (2015)
Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed
Transplantation, 99 (3), 528-32
DOI 10.1097/TP.0000000000000384, PubMed 25148382

Publications 2014

Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K (2014)
More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients
Transplantation, 97 (12), 1266-71
DOI 10.1097/01.TP.0000443225.66960.7e, PubMed 24521776

Sæves I, Line PD, Bremer S, Vethe NT, Tveit RG, Meltevik TJ, Bergan S (2014)
Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation
Ther Drug Monit, 36 (1), 46-53
DOI 10.1097/FTD.0b013e31829dcb66, PubMed 24081206

Vethe NT, Ali AM, Reine PA, Andersen AM, Bremer S, Line PD, Rootwelt H, Bergan S (2014)
Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid
Ther Drug Monit, 36 (1), 108-18
DOI 10.1097/FTD.0b013e3182a13900, PubMed 24061448

Publications 2013

Reine PA, Vethe NT, Kongsgaard UE, Andersen AM, Line PD, Ali AM, Bergan S (2013)
Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring
Scand J Clin Lab Invest, 73 (2), 117-24
DOI 10.3109/00365513.2012.745947, PubMed 23281843

Publications 2012

Fagermoen E, Sulheim D, Winger A, Andersen AM, Vethe NT, Saul JP, Thaulow E, Wyller VB (2012)
Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial
BMC Res Notes, 5, 418
DOI 10.1186/1756-0500-5-418, PubMed 22871021

Publications 2011

Midtvedt K, Jenssen T, Hartmann A, Vethe NT, Bergan S, Havnes K, Åsberg A (2011)
No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus
Nephrol Dial Transplant, 26 (11), 3767-72
DOI 10.1093/ndt/gfr153, PubMed 21471328

Sæves I, Vethe NT, Bergan S (2011)
Quantification of 6 glucocorticoids in human plasma by liquid chromatography tandem mass spectrometry: method development, validation, and assessment of matrix effects
Ther Drug Monit, 33 (4), 402-10
DOI 10.1097/FTD.0b013e3182241799, PubMed 21743383

Vethe NT, Midtvedt K, Asberg A, Amundsen R, Bergan S (2011)
[Drug interactions and immunosuppression in organ transplant recipients]
Tidsskr Nor Laegeforen, 131 (20), 2000-3
DOI 10.4045/tidsskr.11.0138, PubMed 22016125

Publications 2010

Vethe NT, Gjerdalen LC, Bergan S (2010)
Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance
Scand J Clin Lab Invest, 70 (8), 583-91
DOI 10.3109/00365513.2010.531141, PubMed 21039189

Publications 2009

Amundsen R, Asberg A, Robertsen I, Vethe NT, Bergan S, Hartmann A, Midtvedt K (2009)
Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients
Transplantation, 87 (8), 1221-4
DOI 10.1097/TP.0b013e31819f1001, PubMed 19384170

Bremer S, Vethe NT, Rootwelt H, Jørgensen PF, Stenstrøm J, Holdaas H, Midtvedt K, Bergan S (2009)
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J Transl Med, 7, 64
DOI 10.1186/1479-5876-7-64, PubMed 19635156

Vethe NT (2009)
Molecular pharmacodynamics of the immunosuppressant mycophenolic acid: a basis for monitoring and individualized treatment
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 741, 1 b. (flere pag.)
BIBSYS 091766974, ISBN 978-82-8072-780-0

Publications 2008

Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, Midtvedt K, Bergan S (2008)
Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Transplantation, 85 (1), 55-61
DOI 10.1097/01.tp.0000296854.68123.03, PubMed 18192912

Bremer S, Vethe NT, Rootwelt H, Bergan S (2008)
Expression of IMPDH1 is regulated in response to mycophenolate concentration
Int Immunopharmacol, 9 (2), 173-80
DOI 10.1016/j.intimp.2008.10.017, PubMed 19010451

Vethe NT, Bremer S, Bergan S (2008)
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine
Scand J Clin Lab Invest, 68 (4), 277-85
DOI 10.1080/00365510701724871, PubMed 18609073

Vethe NT, Bremer S, Rootwelt H, Bergan S (2008)
Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals
Ther Drug Monit, 30 (6), 647-55
DOI 10.1097/FTD.0b013e31818955c3, PubMed 18806697

Publications 2007

Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JL, Holdaas H (2007)
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol Dial Transplant, 23 (3), 1048-53
DOI 10.1093/ndt/gfm632, PubMed 17956893

Publications 2006

Vethe NT, Bergan S (2006)
Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy
Ther Drug Monit, 28 (5), 608-13
DOI 10.1097/01.ftd.0000245680.38143.ca, PubMed 17038874

Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S (2006)
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
Scand J Clin Lab Invest, 66 (1), 31-44
DOI 10.1080/00365510500420259, PubMed 16464785

Publications 2002

Vethe NT (2002)
Effekten av mykofenolat på IMP-dehydrogenase ved immunsuppressiv behandling av nyretransplanterte pasienter
N.T. Vethe, Oslo, 59, vi s.
BIBSYS 022449574